These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 33956075)

  • 21. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
    JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
    Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
    Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Initial Aflibercept, Laser, or Observation on Low-Contrast Visual Acuity in Eyes With Diabetic Macular Edema and Good Vision: Ancillary Study Within a Randomized Clinical Trial.
    Beaulieu WT; Glassman AR; Baker CW; Maguire MG; Johnson CA; Melia M; Sun JK;
    Transl Vis Sci Technol; 2021 Mar; 10(3):3. PubMed ID: 34003937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
    Baker CW; Glassman AR; Beaulieu WT; Antoszyk AN; Browning DJ; Chalam KV; Grover S; Jampol LM; Jhaveri CD; Melia M; Stockdale CR; Martin DF; Sun JK;
    JAMA; 2019 May; 321(19):1880-1894. PubMed ID: 31037289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.
    Alsoudi AF; Wai KM; Koo E; Parikh R; Mruthyunjaya P; Rahimy E
    JAMA Ophthalmol; 2024 Jul; 142(7):662-668. PubMed ID: 38842828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
    Sivaprasad S; Prevost AT; Vasconcelos JC; Riddell A; Murphy C; Kelly J; Bainbridge J; Tudor-Edwards R; Hopkins D; Hykin P;
    Lancet; 2017 Jun; 389(10085):2193-2203. PubMed ID: 28494920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
    Yang CS; Hung KC; Huang YM; Hsu WM
    J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial.
    Kalra G; Wykoff C; Martin A; Srivastava SK; Reese J; Ehlers JP
    Ophthalmol Retina; 2024 Feb; 8(2):116-125. PubMed ID: 37696393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
    Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
    Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK
    Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Alagorie AR; Nittala MG; Velaga S; Zhou B; Rusakevich AM; Wykoff CC; Sadda SR
    JAMA Ophthalmol; 2020 Aug; 138(8):851-857. PubMed ID: 32584384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs of Managing Diabetic Macular Edema With Good Visual Acuity With Aflibercept, Laser, or Observation: DRCR Retina Network Protocol V.
    Hutton DW; Glassman AR; Stein JD; Bressler NM; Sun JK;
    Am J Ophthalmol; 2021 Oct; 230():297-302. PubMed ID: 33713680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.
    Sinawat S; Rattanapakorn T; Sanguansak T; Yospaiboon Y; Sinawat S
    Eye (Lond); 2013 Dec; 27(12):1391-6. PubMed ID: 24037235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage.
    Li S; Yang Y; Zou J; Zeng J; Ding C
    BMC Ophthalmol; 2022 Feb; 22(1):63. PubMed ID: 35139812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.
    Maguire MG; Liu D; Bressler SB; Friedman SM; Melia M; Stockdale CR; Glassman AR; Sun JK;
    JAMA Ophthalmol; 2021 Dec; 139(12):1266-1273. PubMed ID: 34673898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.
    Maguire MG; Liu D; Glassman AR; Jampol LM; Johnson CA; Baker CW; Bressler NM; Gardner TW; Pieramici D; Stockdale CR; Sun JK;
    JAMA Ophthalmol; 2020 Mar; 138(3):285-293. PubMed ID: 31999300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.